Some weight reduction agents and classes of antidiabetes drugs such as incretin-mimetics and pioglitazone show promising therapeutic potentials. The dual GIP/GLP-1 receptor co-agonist could lead to 20% of weight reduction in addition to significant steatosis reduction. Here, GLP1R is linked to steatosis.